Company news

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) news

Every Crinetics Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) news

Press releases & updates

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics...

Vertex to Acquire Crinetics Pharmaceuticals

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults

Crinetics Pharmaceuticals : Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals : Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dos...

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumel...

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somat...

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO ...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025

Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clini...

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)